ArticleBMC pulmonary medicine2025
Clinical-imaging and therapeutic evaluation of nodule-mass pulmonary cryptococcosis and pneumonia-type pulmonary cryptococcosis.
Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Based on a radiomics-clinical nomogram to predict the therapeutic effect of pulmonary cryptococcosis pneumonia.Scientific reports · 2026Article
- Pulmonary cryptococcosis beyond human immunodeficiency virus: a five-year cohort study of diagnostic challenges, radiologic mimics, and clinical predictors.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe different morphological changes of pulmonary cryptococcosis (PC) cause difficulties in diagnosis and treatment. To evaluate the clinical-imaging and therapeutic differences between nodule-mass PC and pneumonia-type PC. MATERIALS AND
methodsThe clinical-imaging data of 68 patients with PC were collected, including nodule-mass PC (36 cases) and pneumonia-type PC (32 cases). Their clinical-imaging findings were retrospectively analyzed to determine the independent discriminators. Their diagnostic and therapeutic effects were compared.
resultsCompared with nodule-mass PC, pneumonia-type PC was more common with respiratory symptoms (19.4% vs. 81.3%, P < 0.001), inflammatory response (16.7% vs. 71.9%, P < 0.001), bilateral distribution (16.7% vs. 68.8%, P < 0.001), mediastinal lymphadenopathy (0 vs. 21.9%, P = 0.010) and pleural effusion (0 vs. 25%, P = 0.005). While CT malignant signs were more common in nodule-mass PC (66.7% vs. 12.5%, P < 0.001). Multivariate logistic regression analysis showed respiratory symptoms, inflammatory response, bilateral distribution, and malignant CT signs were independent discriminators, with moderate areas under the curve (AUC, 0.760-0.809). Their combined efficacy was significantly improved, with the highest AUC (0.937). Unlike pneumonia-type PC, nodule-mass PC was often treated with low-dose, short-term monofluconazole treatment. However, both groups showed good therapeutic effects.
conclusionRespiratory symptoms, inflammatory response, bilateral distribution, and malignant CT signs were different between nodule-mass PC and pneumonia-type pulmonary PC. Combining these independent discriminators could reveal its clinical-imaging diversity. The graded antifungal therapy based on CT morphology was effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.